Wave Life Sciences (Nasdaq: WVE) details 2025 milestones, cash and executive pay

Wave Life Sciences (WVE) filed an amendment to its 10-K report, providing detailed information on its directors, executive officers, corporate governance, and executive compensation for 2025. The company highlighted significant business milestones, including progress in obesity and Duchenne muscular dystrophy programs, a major collaboration with GSK, and a successful $402.5 million equity financing that resulted in $602.1 million in cash and cash equivalents by year-end 2025. Executive compensation, supported by over 99% shareholder approval, includes performance-based cash bonuses, multi-year option, and RSU grants, aligning executive interests with long-term shareholder value creation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin